Oncimmune

The relationship between the microbiome and disease is complex, with variability in microbiome composition posing a significant challenge to defining standardised biomarkers. While correlations between microbiome changes and disease have been observed, establishing causation remains difficult. Antibody biomarkers, such as autoantibodies and IgA profiling, offer a reproducible method to track immune responses to microbiome imbalances, providing valuable insights into disease mechanisms. Oncimmune’s ImmunoINSIGHTS™ platform enables high-throughput antibody profiling to support biomarker discovery and precision medicine approaches in microbiome-related research. Interested in finding out more? Email us at: immunoinsights@oncimmune.com #MicrobiomeResearch #Biomarkers #PrecisionMedicine #LifeSciences #Immunology

Oncimmune’s George Savidis, MBA, Associate Director, will be at the #Neuroimmunology Drug Development Summit, and is looking forward to engaging with industry leaders in #pharma and #biotech. If you're interested in discussing how #autoantibody profiling can support drug development in neuroimmunology, reach out to George directly to schedule a meeting.

Following the latest #trading update, CEO Martin Gouldstone, Oncimmune spoke to Vox Markets and discussed the company's current demand picture, pipeline and August FY25 guidance. Listen more here: https://lnkd.in/dVqxkywC

The diagnosis of #Sjögren’s disease in patients without #autoantibodies against Ro/SSA is a major challenge. Oncimmune, Hannover Medical School, Università degli Studi di Udine, chariteberlin, and Cell Trend GmbH aimed to identify novel autoantibodies in SjD that may facilitate the diagnostic procedure for Ro/SSA negative SjD. Read our latest paper here: https://lnkd.in/d2Z5tkTm

Identifying IgE autoantibodies provides valuable insights into disease mechanisms and opens new avenues for research. Specifically, #IgEProfiling helps: 🧬 Validate mechanisms of action for IgE-targeted therapeutics 🧬 Identify specific IgE antibodies involved in disease 🧬 Demonstrate how therapies impact these antibodies At Oncimmune, we’ve developed an advanced IgE detection assay capable of measuring #IgE binding to 384 antigens with precision, driving innovation in #immunology and #DrugDevelopment. Interested in learning how we can support your research and development efforts? Contact us today at info@oncimmune.com.

Meet Oncimmune at #PMWC2025 - Our Partnerships Manager, Elena Chavez, will be attending PMWC in Silicon Valley at the Santa Clara Convention Center from February 5-7. If you're exploring cutting-edge advancements in #autoantibody profiling, immunology, or biomarker discovery, connect with Elena directly to discuss how Oncimmune can support your research and development goals. #Biomarkers #Autoantibodies #PrecisionMedicine #Biopharma

Antibody biomarkers are reshaping how we understand the microbiome's role in health and disease. Explore how these advancements are uncovering new insights into immune regulation and precision medicine in our latest article. #MicrobiomeResearch #PrecisionMedicine #ThoughtLeadership

As the holiday season approaches, it’s the perfect time to pause and reflect on the milestones we’ve achieved together over the past year. At Oncimmune, 2024 has been a year of growth, discovery, and collaboration as we continue to advance the boundaries of autoantibody profiling and precision medicine. Here’s a message from our CEO, Martin Gouldstone, as we wrap up an exciting year: "As the year comes to a close, I would like to take a moment to reflect on what we've achieved together in 2024. At Oncimmune, we've continued to push the boundaries of autoantibody profiling, advancing scientific understanding and strengthening partnerships that bring us closer to meaningful breakthroughs. This progress wouldn’t be possible without our dedicated team, our valued partners, and the trust of our clients who share our vision for improving patient outcomes through precision medicine. As we look forward to 2025, I’d like to thank you all for your continued support and collaboration. Wishing you and your loved ones a wonderful festive season and a healthy, prosperous New Year." From all of us at Oncimmune, thank you for being part of our journey. Wishing you a joyful holiday season and a bright start to the New Year! #HappyHolidays #Autoantibodies #PrecisionMedicine

Oncimmune’s CEO, Martin Gouldstone, speaks with Paul Hill from Vox Markets about the company’s mission, unique selling points, and how the proprietary ImmunoINSIGHTS #autoantibody profiling service supports #biopharma companies in developing and monitoring new drugs and precision medicines. Listen here: https://lnkd.in/ddQc6g-E